Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 72.4% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.

Close
Live Chat

Trade BioNTech BNTX

Sell
 Buy

BioNTech live chart

5m 15m 30m 1h 4h 1d 1w

Instrument Fundamentals

Weekly Search
Weekly
Daily
Date Close Change Change (%) Open High Low

News

Webhose 2025 Jan 21, 09:46

Berenberg Bank Remains a Buy on BioNTech SE (BNTX)

BioNTech SE
Webhose 2025 Jan 17, 11:25

Retireful LLC Makes New $260,000 Investment in BioNTech SE (NASDAQ:BNTX)

BioNTech SE
Webhose 2025 Jan 17, 05:00

Wall Street Analysts Predict a 25.59% Upside in BioNTech (BNTX): Here's What You Should Know

BioNTech SE
Webhose 2025 Jan 14, 11:53

BioNTech Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference | The Manila Times

BioNTech SE
Webhose 2025 Jan 10, 15:00

One biotech stock is 'oncology powerhouse' with 40% upside, says Truist

BioNTech SE
Webhose 2025 Jan 10, 13:38

BioNTech (NASDAQ:BNTX) Now Covered by Analysts at Truist Financial

BioNTech SE
Webhose 2025 Jan 10, 01:25

Promising Oncology Pipeline and Financial Strength Drive BioNTech's Growth Prospects

BioNTech SE
Webhose 2025 Jan 10, 01:12

Truist rates BioNTech a Buy, citing 40% upside potential with key 2025 readouts By Investing.com

BioNTech SE
Webhose 2025 Jan 08, 02:10

Vaccine stocks rise in premarket trading amid a jump in number of flu cases By Investing.com

BioNTech SE
Webhose 2025 Jan 07, 19:43

Moderna Jumps 11% on Covid and Bird Flu News, Outperforming Falling Nasdaq 100

BioNTech SE
Webhose 2025 Jan 07, 17:43

BioNTech (NASDAQ:BNTX) Sees Strong Trading Volume - Time to Buy?

BioNTech SE
Webhose 2025 Jan 07, 16:19

BioNTech Sees Unusually Large Options Volume (NASDAQ:BNTX)

BioNTech SE
Webhose 2025 Jan 07, 15:50

Why Vaccine Stocks, Lucid (LCID) Are Rallying

BioNTech SE
Webhose 2025 Jan 07, 04:54

Moderna stock gains on rising flu cases By Investing.com

BioNTech SE
Webhose 2025 Jan 04, 09:30

Head-To-Head Review: Alector (NASDAQ:ALEC) and BioNTech (NASDAQ:BNTX)

BioNTech SE
Webhose 2025 Jan 03, 08:00

Penn expecting $467M from COVID-19 vaccine royalty dispute - WHYY

BioNTech SE
Webhose 2025 Jan 02, 22:01

Acuitas Fights GSK Claims on Pfizer, BioNTech's Covid-19 Shot

BioNTech SE
Webhose 2025 Jan 01, 08:24

Franklin Resources Inc. Sells 4,996 Shares of BioNTech SE (NASDAQ:BNTX)

BioNTech SE
Webhose 2024 Dec 30, 00:00

Biontech's $1.26B vaccine royalty settlement clears path forward | BioWorld

BioNTech SE
Webhose 2024 Dec 28, 19:47

BioNTech to pay $467M in settlement agreement with University of Pennsylvania

BioNTech SE
Webhose 2024 Dec 27, 16:39

BioNTech to Pay Up to $1.26 Billion in Covid-19 Vaccine Settlements With NIH, Penn | Morningstar

BioNTech SE
Webhose 2024 Dec 27, 15:11

BioNTech Enters Into Settlements With U.S. Agency, UPenn Over COVID-19 Vaccine Royalties

BioNTech SE
Webhose 2024 Dec 27, 12:58

BioNTech settles with U.S. agency, University of Pennsylvania over Covid vaccine royalties

BioNTech SE
Webhose 2024 Dec 27, 11:51

BioNTech to Pay US, UPenn $1.3B in COVID Vaccine Royalties

BioNTech SE
Webhose 2024 Dec 27, 08:16

BioNTech SE (NASDAQ:BNTX) Receives $140.76 Consensus Target Price from Brokerages

BioNTech SE
Webhose 2024 Dec 27, 05:00

BioNTech enters settlement with US agency, UPenn over COVID vaccine royalties | U.S. & World | gazette.com

BioNTech SE
Webhose 2024 Dec 27, 04:54

BioNTech enters settlement with US agency, UPenn over COVID vaccine royalties By Reuters

BioNTech SE

Latest news

Info

Spread

1.3096

Spread (%)

1.1460 %

Leverage

1:5

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Markets closed

Thursday

14:31 - 20:59

Monday

14:31-20:59

Tuesday

14:31-20:59

Wednesday

14:31-20:59

Friday

14:31-20:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

28109514752

Shares Outstanding

239740000

Earnings Date (Next)

0000-00-00

Div Yield

2022-06-17

Ex-Dividend Date

2022-06-02

Forward annual dividend rate

0

Forward annual dividend yield

0

EPS

-2

Learn more about this instrument

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac

Related Instruments

Asset
Sell
Buy
Change (%)

Trade Now

Trade Now

Trade Now

Trade Now
view_all_instruments
Trustpilot
Live Chat